JITTERBIT
Jitterbit, the API transformation company, has revealed its first ever Integration Trends Report. It gives an unparalleled view of how companies responded to the seismic challenges of the global pandemic - and how they are building back stronger.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005727/en/
Analysing anonymised data of over 2,000 customers across EMEA from 2020 - 2021, the report reveals macro trends across markets as companies innovated to meet rapidly changing customer needs, move more of their services online and enable remote working for employees.
“The trends emerging all point to a need to move quickly and provide the highest level of product, service and employee experience in order to compete and survive, with companies turning to no-code/ low-code and microservices in readiness for the next stage of hypergrowth. ” said Steve Sichtman, VP Multi Channel Development, Jitterbit
Rather than freeze or reduce spend on integrating new technologies, companies actively sought to spend more on integration across a number of key areas:
Service Experience and eCommerce Spend
- With many physical locations closed or severely disrupted in 2020 and unprecedented customer demand for online service, companies responded by increasing their eCommerce integration investment by 99% during the year.
- Companies increased spend on Services Experience 360 on average by 50% in 2020. Growth in the services front-end with applications such as BMC Helix ITSM, Jira, Zendesk and others was also matched with growth in the services back-end around IT operations.
Product Experience
- Companies increased their spend on Product 360 (optimizing the product life cycle) in 2020 by 26%.
- Data from 2020 reveals a double digit increase in demand around large ERP systems from vendors like SAP and Microsoft. Optimizing business processes was a key focus as businesses realized the essential value of having automated processes across the entire manufacturing, supply chain and sales processes.
Employee Experience
- Companies increased their spend on Employee Experience 360 in 2020 by 72%. Increased reliance on a remote workforce, new communications tools, and fluctuating budgets all contributed to this increased focus on employee experience.
Low-code, microservice and marketplace popularity
- Low-code and no-code gained popularity because of the many hyper automation benefits it offers to IT teams, becoming in the process a key differentiator when selecting an integration platform-as-a-service (iPaaS).
- Many companies have already moved to microservices, rather than API, architecture. Self-contained and ready to go, microservices can be plugged into a wide array of applications and leveraged throughout an organization. Now, there’s evidence of increased demand for iPaaS systems that work closely with microservices. This empowers business users to plug different microservices together to create specialized applications without no-code.
- Many Enterprise and Software companies are finding it’s no longer sufficient to offer an API for the outside world to connect to them. They must overcome the “integration burden” to improve retention and stickiness. The answer lies in integration marketplaces where companies can offer pre-built and certified API integrations and solutions to their partners and customers.
This Integration Trends report demonstrates how trends in integration technology - the way modern businesses automate the connections between the myriad softwares, platforms and technologies they deploy - reflect how businesses respond to meet the macro challenges and opportunities they face.
The report also provides actionable insights on what businesses now need to focus on as countries across EMEA move into the post-pandemic period.
To download the full report, visit: https://info.jitterbit.com/jitterbit-trends-report.html
Ends.
About Jitterbit, Inc.
Jitterbit, the API transformation company, makes it quicker and easier for businesses to exploit data from any source, empowering them to rapidly innovate and make faster, more effective decisions. The Jitterbit Harmony API integration platform and API360 solutions enable companies to quickly connect SaaS, on-premises, and cloud applications and instantly infuse intelligence into any business process. To learn more, visit www.jitterbit.com or follow us on LinkedIn and on Twitter at @Jitterbit .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005727/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom